BRIEF-Oncbiomune awaits approval from regulatory committee to commence phase 2 trial of proscavax

* Oncbiomune awaits approval from regulatory committee tocommence phase 2 trial of proscavax as front line prostatecancer treatmentSource text for Eikon:Further company coverage:
The post BRIEF-Oncbiomune awaits approval from regulatory committee to commence phase 2 trial of proscavax appeared first on RocketNews | Top News Stories From Around the Globe.